<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849160</url>
  </required_header>
  <id_info>
    <org_study_id>CREPATS 001</org_study_id>
    <nct_id>NCT00849160</nct_id>
  </id_info>
  <brief_title>Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.</brief_title>
  <acronym>RADAR</acronym>
  <official_title>Non-comparative, Opened Study, Evaluating in HIV-1 Infected Patients With Undetectable Viral Load, Treated by an Antiretroviral Combination Including a Protease Inhibitor Boosted With Ritonavir and Administered by Oral Route Twice a Day, the Substitutability of the Current Protease Inhibitor Regimen by the Association Darunavir/Ritonavir 800/100 mg Once a Day to Maintain the Viral Load Under the 50 Copies/ml Limit of Detection After 24 Weeks of Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Darunavir boosted with ritonavir (darunavir/r) is a powerful protease inhibitor, able to&#xD;
      reduce the viral load in patients infected with multi-resistant HIV strains; In vitro and in&#xD;
      vivo studies have shown that the induction of resistance mutations in the protease gene is&#xD;
      much more difficult with the association darunavir/r compared to the other ritonavir-boosted&#xD;
      protease inhibitors (PI/r), testifying of a significantly higher genetic barrier to&#xD;
      resistance. Moreover, the tolerance to darunavir is good, and the pharmacologic profile of&#xD;
      this molecule allows a once daily administration with a 800/100 mg dose in patients infected&#xD;
      with a wild HIV strain or with a slightly resistant to darunavir/r strain.&#xD;
&#xD;
      Thus, we propose to evaluate the efficacy of the darunavir/r association once daily as a&#xD;
      substitute to a protease inhibitor regimen administered twice daily in patients with&#xD;
      undetectable viral load receiving a tritherapy including a protease inhibitor administered&#xD;
      twice daily.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable viral load ( &lt; 50 copies/ml)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable viral load under 50 copies/ml</measure>
    <time_frame>All visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the situation of virologic failure defined as a viral load higher than 50 copies/ml confirmed with a second examen at least two weeks later.</measure>
    <time_frame>All visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 lymphocytes count and evolution</measure>
    <time_frame>All visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids balance evolution</measure>
    <time_frame>All visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment tolerance</measure>
    <time_frame>All visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of the darunavir/r concentrations variability and correlation with the potential adverse events and/or virologic failures.</measure>
    <time_frame>All visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spermatic viral load (sub-study concerning 15 patients)</measure>
    <time_frame>Day 0 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacologic sub-studies</measure>
    <time_frame>All visits</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Darunavir/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir</intervention_name>
    <description>darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment</description>
    <arm_group_label>Darunavir/r</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infected patients&#xD;
&#xD;
          -  Treatment with an association of 3 molecules including two Nucleotidic Reverse&#xD;
             Trasncriptase Inhibitors and a ritonavir-boosted protease inhibitor BID, unchanged for&#xD;
             at least one month&#xD;
&#xD;
          -  At least two documented undetectable viral loads (under 50 copies/ml) within the last&#xD;
             3 months&#xD;
&#xD;
          -  Naiive from darunavir&#xD;
&#xD;
          -  Free from any opportunistic infection&#xD;
&#xD;
          -  Creatinin &lt; 3N&#xD;
&#xD;
          -  ASAT &amp; ALAT &lt; 5N&#xD;
&#xD;
          -  Haemoglobin &gt; 7 g/dl&#xD;
&#xD;
          -  Platelets &gt; 50 000/mm3&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing potential and use of a mechanic&#xD;
             contraceptive during sexual relationships&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-2 infected patients&#xD;
&#xD;
          -  Treatment different from the association described in the inclusion criteria (2 NRTIs&#xD;
             + 1 PI/r BID)&#xD;
&#xD;
          -  Patients with a documented problem of treatment compliance within the last 12 months&#xD;
&#xD;
          -  Ongoing active treatment against any opportunistic infection or tuberculosis&#xD;
&#xD;
          -  Any critic concomitant condition (alcohol consumption, fatigue) that may jeopardize&#xD;
             treatment compliance and/olr tolerance, and interfere with the protocol compliance&#xD;
&#xD;
          -  Any concomitant treatment that may potentialize or inhibit hepatic cyotchrome-based&#xD;
             enzymes&#xD;
&#xD;
          -  Patient already treated with darunavir&#xD;
&#xD;
          -  Patient treated with tipranavir, enfuvirtide, raltegravir, etravirine, and/or&#xD;
             maraviroc&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jade Ghosn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hsopitalier Universitaire de Bicêtre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Katlama, MD</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Hospitalier Pitié-Salpêtrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bicêtre - Service de Médecine Interne et Maladies Tropicales</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière - Service de Médecine Interne</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié-Salpêtrière - Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades - Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon - Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2009</study_first_posted>
  <last_update_submitted>January 21, 2014</last_update_submitted>
  <last_update_submitted_qc>January 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

